This event is a welcoming opportunity for patients to learn more about active surveillance, connect with others on a similar journey, and build a supportive community. Whether you're newly diagnosed or have been on surveillance for a while, you are warmly invited to be part of this conversation.

The US Food and Drug Administration (FDA) recently approved lutetium Lu 177 vipivotide tetraxetan (also known by the trade name PLUVICTO®) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and who are considered appropriate to delay…